The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about many questions as hospitals and blood centers prepare to order the testing. We've put together a FAQ document to clarify what we know today. We will update the document as we get more information on existing questions and as new questions get asked, and will update the blog with the revised FAQ document.
Thanks for your support as we work to rapidly get this testing available to you. You can find the FAQ document here: CTS COVID-19 Questions and Answers
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...